{
  "id": 18640976,
  "title": "HCA Healthcare EVP Michael Schlosser sells $593,582 in stock",
  "url": "https://urgent.news/2026/11/07/hca-healthcare-evp-michael-schlosser-sells-593-582-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-07T04:30:57.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/hca-healthcare-evp-michael-schlosser-sells-593582-in-stock-93CH-5009633"
  },
  "original_language": "en",
  "account": "Michael J. Schlosser, HCA Healthcare's Executive Vice President and Chief Clinical Officer, sold 1,200 shares of the company's stock on November 4, 2026, for a total of $593,582. The shares were sold at prices between $494.63 and $494.70, with a weighted average price of $494.6524 per share. Following the sale, Schlosser owned 1,443.1027 shares directly and indirectly held 6,951 shares through a 2022 Trust. HCA Healthcare, valued at $106 billion with a P/E ratio of 16.36, appeared undervalued according to InvestingPro analysis. The company reported strong third-quarter 2026 results, exceeding earnings expectations and generating revenue above forecasts. However, HCA healthcare noted a $400 million unfavorable impact on adjusted EBITDA due to a shift in the payer mix. Despite the strong performance, management indicated consistent 2027 earnings, potentially dampening investor enthusiasm. BofA Securities raised the price target for HCA Healthcare from $450 to $500, citing benefits from supplemental Medicaid programs and solid execution.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}